Back to top

Analyst Blog

Zacks Equity Research

J&J Beats, Adjusts Outlook

JNJ MRK

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Johnson & Johnson (JNJ - Analyst Report) posted third quarter 2011 earnings (excluding special items) of $1.24 per share, three cents above the Zacks Consensus Estimate of $1.21 and 0.8% above the year-ago earnings of $1.23.

Johnson & Johnson’s revenues for the reported quarter increased 6.8% year-over-year to $16 billion. Revenues were in-line with the Zacks Consensus Estimate. Operational factors and foreign exchange movement favorably impacted sales by 2.6% and 4.2%, respectively.

Including one-time items, Johnson & Johnson reported earnings of $1.15, 6.5% below the year-ago earnings of $1.23.

The Quarter in Detail

Third quarter sales declined 3.7% in the domestic market. Meanwhile, international sales increased 16.4%, consisting of 8.3% operational growth and 8.1% favorable currency impact.

The Medical Devices & Diagnostics segment posted sales of $6.3 billion, up 6.1% year-over year. Operational factors and foreign exchange movement positively impacted Medical Devices & Diagnostics segment sales by 1.7% and 4.4%, respectively. Sales in the domestic market declined 0.7% to $2.8 billion; international market sales increased 12.3% to $3.5 billion. Favorable currency movement helped drive international sales.

Primary contributors to growth included Biosense Webster's electrophysiology business, Diabetes Care, Vision Care, DePuy, Ethicon's surgical care products and Ethicon Endo-Surgery's minimally invasive and advanced sterilization products. The Cardiovascular Care franchise continued to record a decline in sales with performance being impacted by competitive pressures in the drug-eluting stent market.

Pharmaceutical segment sales increased 8.9% year-over-year to $6 billion (operational growth of 4.9% and positive currency impact of 4%). Sales in the domestic market declined 6.1% to $2.9 billion whereas the international market grew 27.5% to $3.1 billion. US sales were impacted by the genericization of Levaquin. This was partially offset by strong performances of recently launched products like Zytiga, Stelara, Simponi and Invega Sustenna. Johnson & Johnson also recorded incremental sales due to the amendment of its distribution agreement with Merck (MRK - Analyst Report) for Remicade.

The Consumer segment recorded revenues of $3.7 billion in the reported quarter, up 4.9% from the third quarter of 2010. While operational factors increased sales in the segment by 0.5%, foreign currency movement favorably impacted sales by 4.4%. Sales in the domestic market declined 4.5% year-over-year to $1.2 billion, whereas the international market recorded a 10.1% year-over-year increase to $2.5 billion.

The series of OTC product recalls and the suspension of manufacturing at Fort Washington facility hampered US sales. Third quarter 2011 OTC pharmaceuticals and nutritional sales declined 5% with US sales declining 24.2% mainly due to supply constraints.

Earnings Guidance Adjusted

Following the release of third quarter results, Johnson & Johnson increased the lower end of its 2011 adjusted earnings guidance by five cents to $4.95 - $5.00 per share (old guidance: $4.90 - $5.00 per share). The Zacks Consensus Estimate for 2011 currently stands at $4.96 per share.

Neutral on Johnson & Johnson

We currently have a Neutral recommendation on Johnson & Johnson. The stock carries a Zacks #3 Rank (short term Hold rating). Our Neutral recommendation on the stock is based on the belief that Johnson & Johnson’s diversified business model, lack of cyclicality and strong financial position will help it in tough situations. Johnson & Johnson has been trying to offset the declining sales of some of its important products by bringing in new products through in-licensing deals and acquisitions. We believe the diversity and strength of Johnson & Johnson’s businesses will continue to provide strong growth in future.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%